Cell Line Development Market: Current Analysis and Forecast (2022-2028)

The process of cultivating and maintaining a population of cells in the laboratory for research or therapeutic purposes is referred to as "cell line development." The process usually begins with the isolation of cells from a tissue or organ and continues with the culture-based propagation of the cells.

The Cell Line Development Market is expected to grow at a strong CAGR of 10% during the forecast period owing to the growing demand for biologics and advancements in cell culture technology. With the increasing prevalence of chronic diseases and the need for more effective treatments, the demand for biologics has been growing rapidly. Moreover, the recent advancements in cell culture technology have made it easier and more efficient to develop cell lines, which has led to increased adoption of cell line development services, particularly in the pharmaceutical and biotechnology industries. For instance, Cadila Pharmaceuticals (Cadila) introduced NuPTH, a teriparatide biologic, and Cadalimab, a similar biologic to the auto-immune treatment adalimumab, in the Indian market in October 2021.

Based on cell line, the market is segmented into recombinant, hybridomas, continuous cell line, and primary cell line. Amongst these, the recombinant segment dominated the market in 2021. The recombinant segment increases the production of high levels of a particular protein of interest. This is used extensively in drug development. Adding to this, to create a stable cell line, the segment is inserted into the host cell's genome, and cells with high expression levels are selected and cultured. primary cell line is expected to grow with a significant CAGR during the forecast period.

Based on product, the market is segmented into reagents and media, equipment, finished cells, and others. Amongst these, the reagents and media segment is expected to grow with a significant CAGR during the forecast period. Reagents widely used in cell culture experiments, such as growth factors, antibiotics, and media. While media is the liquid or solid nutrient medium that is used to support the growth of cells in culture that can help in cell growth, metabolism, and the production of biological products.

By source, the market is segmented into mammalian cell line and non-mammalian cell line. Among these, the mammalian cell line captured the majority share of the cell line development market in 2021. The major share of cell line development can be attributed to the increasing use of monoclonal antibody sources derived from mammals and the production of high-quality cell lines for research and drug development the increasing demand for biopharmaceuticals has driven the growth of the mammalian cell line market.

On the basis of application, the market is segmented into recombinant protein expression, hybridomas technology, vaccine production, drug discovery, and others. Vaccine production held a major share of the market in 2021 attributed to the need to update existing vaccine formulations and the emergence of new infectious diseases, the demand for vaccines has increased nowadays. This has prompted an expanded interest in cell lines that can be utilized for immunization creation. For instance, CanSino Biologics, based in China, and the National Research Council of Canada collaborated in May 2020 on the clinical development of a COVID-19 vaccine in Canada.

For a better understanding of the market adoption of the Cell line development industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Rest of World. North America dominated the cell line development market in 2021 due to the rising advancements in gene editing technologies, a highly developed biotechnology industry, and favorable government policies and funding initiatives. For instance, Thermo Fisher Scientific made the announcement on March 25, 2021, that the Applied BioSystems Quant Studio 5 Dx Real-Time PCR System's listing with the U.S. Food and Drug Administration (FDA) had been completed. The novel product enables assay developers and clinical laboratories to meet testing requirements and improve their molecular diagnostics workflows. Adding to this, the growing use of cell lines in regenerative medicine and the rising demand for biopharmaceuticals boost the growth of the market in the region.

Some of the major players operating in the market include: GE Healthcare, Lonza, Sartorious AG, WuXi AppTec, Merck KGaA, Selexis SA, Thermo Fisher Scientific Inc., Corning Incorporated, Danaher, ATCC.